A Randomized, Placebo-Controlled, Double-Blinded, Parallel, Phase 2a Study to Evaluate the Safety and Efficacy of LY2623091 in Patients With Primary Hypertension

Trial Profile

A Randomized, Placebo-Controlled, Double-Blinded, Parallel, Phase 2a Study to Evaluate the Safety and Efficacy of LY2623091 in Patients With Primary Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2017

At a glance

  • Drugs LY 2623091 (Primary) ; Spironolactone; Tadalafil
  • Indications Hypertension
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Feb 2017 Results (n=294) assessing population pharmacokinetics of LY-2623091 using patients data from this and other four trials (NCT01427972, NCT02242981, NCT01237899), published in the Journal of Clinical Pharmacology
    • 30 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 20 Jan 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top